Ann: CEO's Update at AGM, page-13

I thought Wheezo was cut to $149 but now it's $99 and yet management maintain their "projection" guidance, I always thought the device was expensive given the regulatory approval was for Class I as it only objectively detect wheezing which doesn't mean asthma attack, what about for COPD??? Where is the clinical trial results for this...?

I said 15c is around the true valuation for this stock but that was before they cut the price down from $299.....likely 10c now given the age demographic of the market is for youngster who are <14 years old.